IL-23 receptor antagonist icotrokinra hit co-primary phase III endpoints in moderate to severe plaque psoriasis, positioning the oral peptide at the forefront of a multibillion-dollar franchise for partners Protagonist Therapeutics Inc. and Johnson and Johnson.
Sanofi SA has synthesized cyclic peptides acting as IL-23 receptor (IL-23R) antagonists reported to be useful for the treatment of psoriasis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and hidradenitis suppurativa.
